CARDIONOVUM GmbH
Miquel Craven-Bartle Capella holds a variety of executive and managerial positions in sales and business management in the healthcare industry, spanning across various regions including North, Central and South America, Asia Pacific, Oceania and Iberia. With a strong educational background including an Executive MBA, Miquel brings a wealth of experience to their current role as Chief Executive Officer at CARDIONOVUM GmbH.
CARDIONOVUM GmbH
CARDIONOVUM, a medical technology company based in Bonn, Germany, develops and commercializes innovative medical devices such as the new generation of DCB and drug-eluting stents for the treatment of coronary and peripheral artery disease. The company’s pioneering range of DCBs is based on the SAFEPAX® paclitaxel coating matrix which has the lowest wash-off rates on the market. The company’s strong commitment to clinical research ensures a continually deepening and expanding evidence-base in support of the clinical benefits of our products. Pioneers in medical devices. The worldwide first CE-approved DCB. With the first DCB market introduction, CARDIONOVUM contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively. CARDIONOVUM consists of R & D staff, with the longest and most profound experience, in developing clinically advanced DCB and DES cardiovascular devices. “Live Deserves the Best”